Skip to content

Patients › General-Health

Plasma rico em plaquetas (PRP) e terapias injetáveis

What the evidence shows for platelet-rich plasma and related injection therapies in tendinopathy, osteoarthritis and rotator cuff disease — where they help and where the data is weak.

Updated Nov 2026
Um tubo de centrífuga com plasma sanguíneo separado.
O PRP concentra as plaquetas do seu próprio sangue e é usado em algumas condições dos tendões e das articulações, com evidências mistas. Kieran Hirpara 4.0

Esta página foi traduzida automaticamente e ainda não foi verificada por um médico. A versão em inglês é a versão oficial.

O que é

O plasma rico em plaquetas, muitas vezes abreviado como PRP, é um tratamento feito a partir do seu próprio sangue. Uma pequena amostra do seu sangue é girada em uma máquina para que as plaquetas sejam separadas e concentradas. As plaquetas são as pequenas partes do sangue que ajudam na coagulação, e elas também carregam fatores de crescimento, que são substâncias naturais que podem favorecer a cicatrização. As plaquetas concentradas são então injetadas na área dolorida.

O seu médico pode considerar o PRP para problemas como a artrose do joelho (artrite do desgaste), problemas de tendões no cotovelo, no ombro ou no punho e algumas lesões musculares no esporte. Ele não é usado para todas as condições. No cotovelo de tenista, as evidências são mistas: alguns estudos verificaram que o PRP funcionou melhor do que as injeções de corticoide a longo prazo [1], enquanto uma revisão de ensaios clínicos não confirmou que ele seja melhor do que o placebo [2]. Na artrose do joelho, muitas vezes são recomendadas duas injeções, com efeitos que duram pelo menos 24 semanas [3]. Na síndrome do túnel do carpo, o PRP mostrou benefícios mais duradouros do que uma injeção de corticoide no acompanhamento de 6 meses [4].

A ideia por trás do PRP é que os fatores de crescimento das plaquetas podem reduzir a inflamação e estimular o reparo dos tecidos. As pesquisas ainda estão esclarecendo os detalhes. Os estudos mostram que preparações diferentes se comportam de formas diferentes: um tipo rico em glóbulos brancos parece adequado para a artrose em fase inicial, enquanto outro, com mais plaquetas e menos glóbulos brancos, pode ser adequado para fases mais avançadas [5]. Alguns ensaios clínicos verificaram que o PRP funcionou melhor do que as injeções de anestésico em problemas dos tendões do ombro e do cotovelo, mas não melhor do que o agulhamento seco ou as injeções de água com sal [6]. De modo geral, as evidências variam de uma condição para outra, e o seu médico vai conversar com você sobre se o PRP faz sentido para o seu problema específico.

Funciona mesmo?

A resposta honesta é que depende da condição e, em alguns casos, as pesquisas ainda estão se atualizando. Uma revisão das evidências concluiu que o PRP é um tratamento potencialmente interessante, mas que ainda não há pesquisas de boa qualidade suficientes para apoiar o seu uso amplo [7]. Os pesquisadores também observaram que alguns resumos de ensaios clínicos sobre o PRP na artrose do joelho apresentam os seus resultados de forma excessivamente positiva, o que pode fazer o tratamento parecer melhor do que as evidências realmente mostram [8].

Para algumas condições, os resultados são mais animadores. Nos problemas de tendões, ensaios clínicos verificaram que o PRP melhorou a dor e o funcionamento da parte afetada, e funcionou melhor do que as injeções de corticoide a médio prazo [9]. Na artrose do joelho, o PRP melhorou a função geral, principalmente em pessoas mais jovens [10]. A combinação do PRP com o ácido hialurônico, uma substância lubrificante encontrada naturalmente nas articulações, proporcionou mais alívio da dor e melhor função do que o PRP sozinho [11].

Para outras condições, o quadro é misto ou incerto. No cotovelo de tenista, alguns ensaios clínicos verificaram que o PRP reduziu a dor e melhorou a função nos primeiros meses [12], enquanto outras pesquisas não o apoiaram como tratamento [2]. Nas rupturas do manguito rotador, não há evidências de boa qualidade suficientes para dizer se ele ajuda ou não [13]. Na cartilagem do joelho danificada, as evidências ainda não apoiam as injeções de PRP isoladamente [14].

O que isso significa para você? O PRP pode ajudar em alguns problemas, mas não é uma solução comprovada para tudo. O seu médico vai explicar o que as evidências mostram para a sua condição específica, para que vocês possam decidir juntos se vale a pena tentar.

Quais são os riscos?

O PRP é feito a partir do seu próprio sangue, por isso é pouco provável que o seu corpo reaja mal ao material em si. Isso não significa que o tratamento seja isento de riscos. A própria injeção pode causar dor, inchaço e rigidez nos dias seguintes, e a área tratada pode ficar dolorida antes de melhorar. O seu médico vai orientar você sobre como lidar com isso.

As pesquisas sobre o PRP na artrose do joelho ainda não resolveram a questão de quão bem ele funciona, e alguns resumos publicados apresentaram os seus resultados de forma excessivamente positiva [8]. Isso importa quando você está avaliando se deve seguir em frente, porque um tratamento que parece promissor pode não trazer o alívio que você espera. No reparo do manguito rotador, acrescentar PRP aumentou as taxas de cicatrização, mas não mudou o quanto os pacientes conseguiam usar o ombro no dia a dia [15]. Nos problemas do tendão de Aquiles, ensaios clínicos verificaram que o PRP não funcionou melhor do que o placebo [16].

A forma como o seu corpo responde também pode depender das suas circunstâncias. Injeções anteriores de corticoide e o uso de tabaco parecem reduzir a eficácia do PRP na epicondilite medial crônica, um problema de tendão na parte de dentro do cotovelo [17]. Se você fuma ou já recebeu injeções de corticoide na mesma área, mencione isso antes de decidir sobre o tratamento.

Algumas questões continuam em aberto. Os pesquisadores observaram que são necessários mais estudos para confirmar os efeitos do PRP a longo prazo [18]. Os estudos sobre o PRP no cotovelo de tenista mostraram resultados mistos: alguns ensaios clínicos relataram alívio precoce da dor e melhora da função [12], e outros não encontraram benefício claro em relação ao placebo [2]. Também ainda não há evidências de boa qualidade suficientes para apoiar as injeções de PRP isoladamente na cartilagem do joelho danificada [14].

Se você notar aumento da dor, da vermelhidão ou do calor ao redor do local da injeção nos dias após o tratamento, entre em contato com o consultório para que possamos examinar. O seu médico vai conversar com você sobre os riscos específicos da sua condição antes de você decidir se vai seguir em frente.

É a opção certa para você?

O PRP costuma ser mais adequado para algumas pessoas do que para outras. Se você tem artrose do joelho (artrite do desgaste), recomendam-se pelo menos duas injeções, com efeitos que duram pelo menos 24 semanas [3]. Se você pratica esporte competitivo, os pesquisadores recomendaram oferecer a terapia com PRP a praticantes de esportes de competição [19]. Se você tem síndrome do túnel do carpo nos dois punhos, o PRP mostrou benefícios mais duradouros do que uma injeção de corticoide no acompanhamento de 6 meses [4].

Há situações em que o PRP tem menos probabilidade de ser a escolha certa. Se você tem cartilagem danificada no joelho, as evidências ainda não apoiam as injeções de PRP isoladamente [14]. No cotovelo de tenista, as evidências são mistas, então ele pode ou não ajudar você. Se você fuma ou já recebeu injeções de corticoide na mesma área, o PRP pode funcionar menos bem para você.

O PRP é uma opção entre várias. As injeções de corticoide são a principal alternativa para algumas condições, e o PRP mostrou benefícios mais duradouros do que os corticoides em alguns casos [4]. Outra opção é o ácido hialurônico, uma substância lubrificante encontrada naturalmente nas articulações. As pesquisas que comparam os dois ainda estão em fase inicial, então o seu médico vai explicar o que se sabe até agora.

Esta deve ser uma decisão compartilhada entre você e o seu médico. Pense nos seus objetivos, na sua condição e no que as evidências mostram sobre ela. O seu médico vai conversar com você sobre as opções, incluindo os riscos descritos na seção acima, para que vocês possam decidir juntos se o PRP faz sentido para você.

Conclusão

Vale a pena considerar o PRP para alguns problemas, mas com expectativas realistas. Ele pode aliviar a dor e melhorar a função na artrose do joelho e em algumas condições dos tendões, embora os resultados variem de pessoa para pessoa. A ressalva mais importante é que as pesquisas ainda estão se atualizando e, para várias condições, ainda não há evidências de boa qualidade suficientes para apoiar o seu uso amplo [7]. O seu médico vai ajudar você a avaliar se ele faz sentido para o seu problema específico.

Referências

[1] A Randomized Controlled Trial of 1-Year Clinical Outcomes of a Single Platelet-Rich Plasma Injection Versus Corticosteroid for the Treatment of Lateral Elbow Tendinopathy. Orthopaedic Journal of Sports Medicine. 2026. DOI: 10.1177/23259671251386862

[2] Platelet-Rich Plasma Does Not Improve Pain or Function in Patients With Lateral Epicondylitis as Compared With Placebo: A Meta-analysis of Randomized Clinical Trials. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465251383039

[3] Efficacy of multiple autologous apheresis platelet-rich plasma injections for treating knee osteoarthritis and its influencing factors: a retrospective cohort study. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05756-6

[4] Comparison of the effectiveness of platelet-rich plasma (PRP) injection and steroid injection in patients with bilateral moderate carpal tunnel syndrome: a prospective randomized controlled trial. Injury. 2026. DOI: 10.1016/j.injury.2026.113018

[5] The efficacy of platelet-rich plasma preparation protocols in the treatment of osteoarthritis: a network meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06026-1

[6] Update on Platelet-rich Plasma for Shoulder and Elbow Tendinopathy. Techniques in Shoulder & Elbow Surgery. 2017. DOI: 10.1097/bte.0000000000000118

[7] Platelet-Rich Plasma for Chronic Tennis Elbow: Letters to the Editor. The American Journal of Sports Medicine. 2014. DOI: 10.1177/0363546513512784

[8] Statistically Significant Results Favored in Abstracts of Platelet Rich Plasma Treatment of Knee Osteoarthritis: A Systematic Review and Spin Analysis. Arthroscopy. 2026. DOI: 10.1002/arj.70027

[9] Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08566-3

[10] Investigating the therapeutic impact of platelet-rich plasma on knee, hip, and traumatic osteoarthritis: a meta-analysis and systematic review. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09486-6

[11] RETRACTED ARTICLE: A meta-analysis and systematic review of the clinical efficacy and safety of platelet-rich plasma combined with hyaluronic acid (PRP + HA) versus PRP monotherapy for knee osteoarthritis (KOA). Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-024-05429-w

[12] Poster 58: Decreased Pain After Platelet-Rich Plasma Injection in Lateral Epicondylitis Patients in the Early Follow-up Period. Orthopaedic Journal of Sports Medicine. 2025. DOI: 10.1177/2325967125s00169

[13] Use of Platelet-Rich Plasma for the Improvement of Pain and Function in Rotator Cuff Tears: Response. The American Journal of Sports Medicine. 2020. DOI: 10.1177/0363546520918190

[14] Orthobiologic Injections Adjunctive to Cartilage‐Preserving Surgery May Improve Outcomes for Focal Knee Chondral Defects: A Systematic Review of Randomized Controlled Trials With Subgroup Meta‐analyses. Arthroscopy. 2026. DOI: 10.1002/arj.70548

[15] Injection of Leukocyte‐Poor Platelet‐Rich Plasma During Rotator Cuff Repair Can Increase Healing Rate but Does Not Affect Clinical Outcomes: A Systematic Review and Meta‐analysis of Randomized Controlled Trials. Arthroscopy. 2026. DOI: 10.1002/arj.70537

[16] Editor’s Spotlight/Take 5: Is Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials. Clinical Orthopaedics & Related Research. 2025. DOI: 10.1097/corr.0000000000003478

[17] Efficacy of platelet-rich plasma injections for chronic medial epicondylitis. Journal of Hand Surgery (European Volume). 2015. DOI: 10.1177/1753193414567012

[18] Overview of Available Treatments and Their Limitations for Hypertrophic Facet Joints—A Systematic Review of the Literature. JAAOS: Global Research and Reviews. 2025. DOI: 10.5435/jaaosglobal-d-24-00140

[19] Platelet-rich plasma treatment for large joint osteoarthritis: retrospective study highlighting a possible treatment protocol with long-lasting stimulation of the joint with an adequate dose of platelets. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08663-3


Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

  • PRP remains a potentially interesting intervention for chronic tennis elbow but currently lacks sufficient high-quality evidence of effectiveness to warrant widespread use [1].
  • PRP therapies for shoulder and elbow tendinopathy have only partially fulfilled therapeutic expectations, necessitating new approaches [2].
  • For knee osteoarthritis, at least two PRP injections are recommended, with effects lasting for at least 24 weeks [3].
  • The conclusions of recent studies on intra-articular PRP for knee osteoarthritis are intended to stimulate further research rather than provide a conclusive statement on efficacy [4].
  • There is no definitive evidence regarding the effectiveness of PRP treatment when the literature is evaluated [5].
  • Further studies are needed to evaluate the long-term efficacy and cost-effectiveness of PRP for practical patient use in hypertrophic facet joints [6].
  • Conclusions regarding the clinical utility of PRP should be interpreted with caution due to major methodological concerns, including lack of PRP characterization and short-term follow-up [7].
  • Leukocyte-rich (L-PRP) and leukocyte-poor (LP-PRP) are effective treatment options for knee osteoarthritis with comparable efficacy based on current evidence [8].
  • PRP may have a potential role as a biological adjunct in fracture nonunion management, but further well-designed randomized controlled trials are required before definitive clinical recommendations can be made [9].
  • PRP injections must be integrated into a comprehensive treatment plan with non-pharmacological measures and post-procedural care that needs to be better defined [10].
  • Interventions employing PRP, MSCs, and exosomes are considered in the context of degenerative osteoarthritis as a reversible chronic disease [11].
  • PRP provides a greater clinical improvement at 12 weeks than a single corticosteroid injection for gluteal tendinopathy [12].
  • PRP demonstrated indications of more sustained benefits, particularly at the 6-month follow-up, in patients with bilateral moderate carpal tunnel syndrome [13].
  • There is insufficient evidence to recommend for or against the use of PRP for rotator cuff tears due to literature heterogeneity and effect sizes failing to reach MCID values even when significant [14].
  • The authors recommend systematically offering PRP therapy for competition sports practitioners with large joint osteoarthritis [16].
  • The authors argue that they fulfilled the reporting requirements for the injected PRP product as defined by MIBO [18].
  • The statement regarding the standard of care for knee osteoarthritis was intended to reflect frequent clinical use of hyaluronic acid and platelet-rich plasma rather than formal guideline recommendations [24].
  • It is recommended to wait for at least one month before considering another injection or alternative treatments for first presentation trigger digits [27].
  • Findings from a meta-analysis of randomized clinical trials do not support PRP as a recommended treatment for lateral epicondylitis [28].
  • The efficacy of autologous platelets is well established, and the study reinforced the previously published report by the author regarding diabetic tibial non-union [51].

How It Works

Mechanisms and Biological Effects

  • PRP enhances anabolic gene expression patterns in flexor digitorum superficialis tendons [34].
  • The effect of PRP on chondrocytes and macrophages is mainly influenced by the age and disease status of the PRP donor rather than inflammatory mediator or growth factor groupings [33].
  • PRP from older males with knee osteoarthritis depresses chondrocyte metabolism and upregulates inflammation [33].
  • Leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP) derived from the same patient with equivalent platelet concentrations have discernible key molecular mediators [32].
  • Low platelet, high leukocyte PRP is recommended for early osteoarthritis due to its anti-inflammatory effects [36].
  • High platelet, low leukocyte PRP is preferred for advanced osteoarthritis to promote tissue repair and regeneration [36].
  • The application of Plasma Rich in Growth Factors (PRGF) in intramuscular infiltrations is an innovative biological approach to the treatment of muscle injuries [31].

Efficacy and Clinical Outcomes

  • PRP demonstrated indications of more sustained benefits, particularly at the 6-month follow-up, compared to steroid injection in bilateral moderate carpal tunnel syndrome [13].
  • Corticosteroids resulted in greater short-term improvement, while PRP demonstrated superior longer-term outcomes at 6 and 12 months for lateral elbow tendinopathy [20].
  • Findings from a randomized controlled trial refute claims of PRP equivalence to placebo and support its efficacy over placebo in chronic tenosynovitis [15].
  • Both leukocyte-rich PRP (L-PRP) and leukocyte-poor PRP (LP-PRP) are effective treatment options with comparable efficacy for knee osteoarthritis based on current evidence [8].
  • LP-PRP augmentation during rotator cuff repair increases healing rates but does not affect clinically meaningful functional outcomes [39].
  • PRP may serve as an adjunct to structured rehabilitation rather than a determinant of long-term strength recovery for lateral epicondylitis [40].
  • A direct, linear relationship was observed between the concentration factor of PRP used and the magnitude of patient-reported symptom relief after PRP injection for lateral epicondylitis [22].
  • High-dose PRP showed significant efficacy over alternative treatment strategies for lateral epicondylitis [22].
  • Although PRP has been reported in literature to be a biological treatment which increases healing, adequate healing was not determined in the patient group of a study on delayed union or non-union [30].
  • PRP remains a potentially interesting intervention for chronic tennis elbow but is currently lacking sufficient high-quality evidence of effectiveness to warrant widespread use [1].
  • PRP therapies have only partially fulfilled therapeutic expectations for shoulder and elbow tendinopathy, and new approaches are necessary [2].
  • The conclusions of a study on intra-articular PRP injections for knee osteoarthritis do not intend to provide a conclusive statement but rather to stimulate further research [4].
  • A prospective, multicenter, double-blind randomized controlled trial for Kellgren-Lawrence Grade I and II knee osteoarthritis does not establish PRP efficacy or component-specific effects because components were bundled and no placebo group was included [19].
  • The authors' conclusions regarding the clinical utility of PRP should be interpreted with caution due to major methodological concerns, including lack of PRP characterization and short-term follow-up [7].

Protocols and Influencing Factors

  • At least two PRP injections are recommended for treating knee osteoarthritis, with effects lasting for at least 24 weeks [3].
  • Previous corticosteroid injections and tobacco seem to unfavourably affect the response to PRP for chronic medial epicondylitis [35].
  • Further studies will be needed to evaluate PRP’s long-term efficacy and cost-effectiveness for practical patient use in the future for hypertrophic facet joints [6].
  • Rigorous basic, translational, and clinical research remains fundamental to realize the promise of PRP treatment for musculoskeletal disease [21].
  • The PRP used in a study on anti-inflammatory and matrix restorative mechanisms came from healthy donors, which may encourage research toward the use of allogeneic healthy PRP [37].
  • A study compared the efficacy of intra-articular injections of platelet-rich plasma (PRP) and viscosupplementation (hyaluronic acid [HA]) for the treatment of knee degenerative cartilage lesions and osteoarthritis [17].

What the Evidence Shows

General Applicability and Methodology

  • PRP remains a potentially interesting intervention but currently lacks sufficient high-quality evidence of effectiveness to warrant widespread use [1].
  • PRP therapies have only partially fulfilled therapeutic expectations, necessitating new approaches [2].
  • Studies evaluating the outcomes and procedures of PRP use in lateral epicondylitis demonstrate poor adherence to MIBO guidelines [26].
  • Spin bias is highly prevalent in the abstracts of systematic reviews and meta-analyses of intra-articular PRP for knee osteoarthritis, with identified spin tending to favor the use of PRP [52].

Knee Osteoarthritis

  • At least two PRP injections are recommended for knee osteoarthritis, with effects lasting for at least 24 weeks [3].
  • The conclusions of studies on intra-articular PRP for knee osteoarthritis intend to stimulate further research rather than provide a conclusive statement [4].
  • Both leukocyte-rich (L-PRP) and leukocyte-poor (LP-PRP) are effective treatment options with comparable efficacy based on current evidence [8].
  • Leukocytes did not affect the safety and efficacy of intra-articular PRP injections for the treatment of patients with knee osteoarthritis [43].
  • PRP + HA therapy is safe and yields better outcomes in pain relief and functional improvement compared to PRP monotherapy for patients with knee osteoarthritis [47].
  • Intra-articular PRP injection is an effective treatment for improving overall function in patients with primary osteoarthritis, particularly in younger individuals [49].
  • PRP demonstrated limited and inconsistent effects on imaging-based structural outcomes in knee osteoarthritis, and did not confer significant and consistent benefits in medial tibial cartilage measurements, cartilage defect progression, synovitis, or most WORMS domains [53].
  • A prospective, multicenter, double-blind randomized controlled trial for Kellgren-Lawrence Grade I and II knee osteoarthritis did not establish PRP efficacy or component-specific effects because components were bundled and no placebo group was included [19].
  • The authors recommend systematically offering PRP therapy for competition sports practitioners in the context of large joint osteoarthritis treatment protocols [16].

Lateral Epicondylitis (Tennis Elbow)

  • A direct, linear relationship was observed between the concentration factor of PRP used and the magnitude of patient-reported symptom relief after PRP injection, with high-dose PRP showing significant efficacy over alternative treatment strategies [22].
  • PRP injections are a safe and effective conservative treatment method for reducing pain symptoms and increasing functionality in patients with lateral epicondylitis in the early follow-up period [48].
  • After autologous blood injection therapy, 22 patients (79%) in whom nonsurgical modalities had failed were relieved completely of pain even during strenuous activity [50].

Rotator Cuff and Shoulder

  • There is insufficient evidence to recommend for or against the use of PRP for rotator cuff tears given the heterogeneity of the literature and the inability of effect sizes to reach MCID values even when significant [14].
  • A significant difference in the retear rate, even in an underpowered study, has further confirmed the positive effect of platelet-rich plasma for arthroscopic repair of medium to large rotator cuff tears [42].
  • Substantial heterogeneity and inconsistent reporting of PRP composition limit the certainty of findings regarding platelet concentration and improved pain for partial-thickness rotator cuff tears treated with PRP [55].

Other Tendinopathies and Musculoskeletal Conditions

  • PRP is no more effective than placebo for treating Achilles tendinopathy and should not be used for this indication until new, large, high-quality RCTs upend current knowledge [41].
  • PRP can effectively improve pain and functional impairment in patients with tendinopathy, and its midterm efficacy is superior to that of corticosteroids [46].
  • A randomized trial found no significant difference in outcomes between LR-PRP and placebo for the treatment of greater trochanteric pain up to 6 months following the intervention [44].
  • Findings from a randomized controlled trial refute claims of PRP equivalence to placebo and support its efficacy over placebo for chronic tenosynovitis [15].
  • PRP demonstrated some indications of more sustained benefits, particularly at the 6-month follow-up, compared to steroid injection in patients with bilateral moderate carpal tunnel syndrome [13].

Fractures, Nonunion, and Bone Pathology

  • The application of PRP following core decompression results in significant pain relief, improved short-term functional outcomes, and enhanced quality of life compared to core decompression alone for early osteonecrosis of the femoral head [45].

Sports Injuries and Adjunctive Procedures

  • Current evidence supports the selective use of PRP in sports settings for acute muscle injuries, though standardization in protocols and outcomes is needed [25].
  • PRP, used as an adjuvant in meniscal repair, may be associated with improved clinical and radiographic outcomes, particularly by reducing failure rates and enhancing PROs [54].
  • Current evidence is insufficient to support orthobiologic injections adjunctive to cartilage-preserving surgery as standalone procedures for focal knee chondral defects [29].

Spine and Facet Joints

  • Further studies will be needed to evaluate PRP’s long-term efficacy and cost-effectiveness for practical patient use in the treatment of hypertrophic facet joints [6].

Practical Considerations

  • Further studies are needed to evaluate PRP’s long-term efficacy and cost-effectiveness for practical patient use in hypertrophic facet joints [6].
  • Both leukocyte-rich (L-PRP) and leukocyte-poor (LP-PRP) are effective treatment options with comparable efficacy for knee osteoarthritis based on current evidence [8].
  • PRP demonstrated some indications of more sustained benefits, particularly at the 6-month follow-up, compared to steroid injection in bilateral moderate carpal tunnel syndrome [13].
  • The authors recommend systematically offering PRP therapy for competition sports practitioners for large joint osteoarthritis [16].
  • A trial evaluating PRP therapy in Kellgren-Lawrence Grade I and II knee osteoarthritis does not establish PRP efficacy or component-specific effects because components were bundled and no placebo group was included [19].
  • Results from an in vitro study regarding the anti-inflammatory and matrix restorative mechanisms of PRP in osteoarthritis should be interpreted with caution [23].
  • Studies evaluating the outcomes and procedures of the use of PRP in the setting of lateral epicondylitis have poor adherence to MIBO guidelines [26].
  • Current evidence is insufficient to support orthobiologic injections as standalone procedures for focal knee chondral defects [29].
  • The economic value of LP-PRP is conditional rather than uniform and depends on revision probability and preparation cost [38].

Key Evidence

  • [L5] The authors conclude that PRP remains a potentially interesting intervention but is currently lacking sufficient high-quality evidence of effectiveness to warrant widespread use. [1] (10.1177/0363546513512784)
  • [L1] PRP therapies have only partially fulfilled therapeutic expectative, and new approaches are necessary. [2] (10.1097/bte.0000000000000118)
  • [L3] At least two PRP injections are recommended, with effects lasting for at least 24 weeks. [3] (10.1186/s13018-025-05756-6)
  • [Paper] The conclusions of this study do not intend to provide a conclusive statement but rather to stimulate further research in this complex field and contribute to shedding light on the several aspects influencing the efficacy of intra-articular platelet-rich plasma (PRP) injections for knee osteoarthritis (OA) in clinical practice. [4] (10.1177/03635465251387701)
  • [L5] When the literature is evaluated, it is understood that there is no definitive evidence regarding the effectiveness of PRP treatment. [5] (10.1177/23259671241255700)
  • [L4] Further studies will be needed to evaluate PRP’s long-term efficacy and cost-effectiveness for practical patient use in the future. [6] (10.5435/jaaosglobal-d-24-00140)
  • [L5] The authors' conclusions regarding the clinical utility of PRP should be interpreted with caution due to major methodological concerns, including lack of PRP characterization and short-term follow-up; future studies should prioritize long-term outcomes to guide clinical decision-making more effectively. [7] (10.1016/j.arth.2025.05.007)
  • [L1] Both L-PRP and LP-PRP are effective treatment options with comparable efficacy based on current evidence. [8] (10.1186/s13018-026-06689-4)
  • [Paper] PRP may have a potential role as a biological adjunct in a fracture nonunion management, but further well-designed randomized controlled trials are required before definitive clinical recommendations can be made. [9] (10.1016/j.injury.2026.113826)
  • [Paper] PRP injections must be integrated into a comprehensive treatment plan with non-pharmacological measures and post-procedural care that needs to be better defined. [10] (10.1016/j.otsr.2026.104972)
  • [L5] Interventions employing PRP, MSCs and exosomes are considered in this article. [11] (10.1016/j.reth.2020.07.007)
  • [L5] The authors state that the conclusion of the referenced randomized controlled trial is that PRP provides a greater clinical improvement at 12 weeks than a single corticosteroid injection. [12] (10.1177/0363546518773719)
  • [L1] PRP demonstrated some indications of more sustained benefits, particularly at the 6-month follow-up. [13] (10.1016/j.injury.2026.113018)
  • [L5] There is insufficient evidence to recommend for or against the use of PRP given the heterogeneity of the literature and the inability of effect sizes to reach MCID values even when significant. [14] (10.1177/0363546520918190)
  • [L1] These findings refute claims of PRP equivalence to placebo and support its efficacy over placebo. [15] (10.1186/s12891-025-09339-8)
  • [L4] The authors recommend systematically offering PRP therapy for competition sports practitioners. [16] (10.1186/s12891-025-08663-3)
  • [Paper] The authors argue that they fulfilled the reporting requirements for the injected PRP product as defined by MIBO. [18] (10.1177/03635465231203202)
  • [L1] Because components were bundled and no placebo group was included, the trial does not establish PRP efficacy or component-specific effects. [19] (10.1177/03635465261486945)
  • [L1] Corticosteroids resulted in greater short-term improvement, while PRP demonstrated superior longer-term outcomes at 6 and 12 months. [20] (10.1177/23259671251386862)
  • [Paper] Rigorous basic, translational, and clinical research remains fundamental to realize the promise of PRP treatment for musculoskeletal disease. [21] (10.1177/03635465251395284)
  • [L1] A direct, linear relationship was observed between the concentration factor of PRP used and the magnitude of patient-reported symptom relief after PRP injection, with high-dose PRP showing significant efficacy over alternative treatment strategies. [22] (10.1016/j.jisako.2025.100442)
  • [L5] The authors agree that results from an in vitro study should be interpreted with caution and mention a subsequent prospective randomized double-blind clinical trial comparing autogenous PRP to HA for the treatment of OA. [23] (10.1177/0363546514537991)
  • [L5] The authors clarify that their statement regarding the standard of care for knee osteoarthritis was intended to reflect frequent clinical use of hyaluronic acid and platelet-rich plasma rather than formal guideline recommendations. [24] (10.1177/0363546517703364)
  • [L2] Current evidence supports the selective use of PRP in sports settings, though standardization in protocols and outcomes is needed. [25] (10.1177/23259671251399907)
  • [L2] This review demonstrated that studies evaluating the outcomes and procedures of the use of PRP in the setting of LE have poor adherence to MIBO guidelines. [26] (10.5397/cise.2024.01060)
  • [L3] It is recommended to wait for at least one month before considering another injection or alternative treatments. [27] (10.1142/s2424835520500253)
  • [L1] These findings do not support PRP as a recommended treatment for this condition. [28] (10.1177/03635465251383039)
  • [L2] Current evidence is insufficient to support such injections as standalone procedures. [29] (10.1002/arj.70548)
  • [L4] Although PRP has been reported in literature to be a biological treatment which increases healing, adequate healing was not determined in the patient group of the current study. [30] (10.1016/s0020-1383(13)70158-x)
  • [L5] An innovative biological approach to the treatment of muscle injuries is the application of Plasma Rich in Growth Factors (PRGF) in intramuscular infiltrations. [31] (10.1016/s0020-1383(14)70004-x)
  • [L5] The goal of the study was to discern key molecular mediators between leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP) derived from the same patient with equivalent platelet concentrations. [32] (10.1177/03635465231206930)
  • [Paper] The effect of PRP on chondrocytes and macrophages was mainly influenced by the age and disease status of the PRP donor as opposed to the inflammatory mediator or growth factor groupings. [33] (10.1002/jor.24322)
  • [Paper] These findings support in vivo investigation of PRP as an autogenous, patient-side treatment for tendonitis. [34] (10.1002/jor.20278)
  • [L4] Previous corticosteroid injections and tobacco seem to unfavourably affect the response to PRP. [35] (10.1177/1753193414567012)
  • [L1] Optimizing OA treatment involves tailoring PRP protocols to disease stage, with low platelet, high leukocyte PRP recommended for early OA due to its anti-inflammatory effects and high platelet, low leukocyte PRP preferred for advanced OA to promote tissue repair and regeneration. [36] (10.1186/s13018-025-06026-1)
  • [L5] The authors also highlight that the PRP used in the study came from healthy donors, which may encourage research toward the use of allogeneic healthy PRP. [37] (10.1177/0363546514537996)
  • [L1] The economic value of LP-PRP is conditional rather than uniform and depends on revision probability and preparation cost. [38] (10.1016/j.jse.2026.02.018)
  • [L1] Consequently, LP-PRP augmentation increases healing rates but does not affect clinically meaningful functional outcomes. [39] (10.1002/arj.70537)
  • [L1] PRP may serve as an adjunct to structured rehabilitation rather than a determinant of long-term strength recovery. [40] (10.1016/j.jse.2026.09.009)
  • [L1] PRP is no more effective than placebo for treating Achilles tendinopathy and should not be used for this indication until new, large, high-quality RCTs upend current knowledge. [41] (10.1097/corr.0000000000003478)
  • [L5] The authors state that the significant difference in the retear rate, even in this underpowered study, has further confirmed the positive effect of platelet-rich plasma (PRP). [42] (10.1177/0363546515625958)
  • [L1] This double-blind randomized controlled trial demonstrated that leukocytes did not affect the safety and efficacy of intra-articular PRP injections for the treatment of patients with knee OA. [43] (10.1177/03635465241283500)
  • [L1] This randomized trial found no significant difference in outcomes between LR-PRP and placebo for the treatment of greater trochanteric pain up to 6 months following the intervention. [44] (10.2106/jbjs.24.00763)
  • [L3] The application of PRP following CD results in significant pain relief, improved short-term functional outcomes, and enhanced quality of life compared to CD alone. [45] (10.1186/s12891-024-08243-x)
  • [L1] PRP can effectively improve pain and functional impairment in patients with tendinopathy, and its midterm efficacy is superior to that of corticosteroids. [46] (10.1186/s12891-025-08566-3)
  • [L1] This meta-analysis reveals that, for patients with KOA, PRP + HA therapy is safe and yields better outcomes in pain relief and functional improvement compared to PRP monotherapy. [47] (10.1186/s13018-024-05429-w)
  • [L4] PRP injections are a safe and effective conservative treatment method for reducing pain symptoms and increasing functionality in patients with lateral epicondylitis. [48] (10.1177/2325967125s00169)
  • [L1] Intra-articular PRP injection is an effective treatment for improving overall function in patients with primary OA, particularly in younger individuals. [49] (10.1186/s12891-026-09486-6)
  • [L4] After autologous blood injection therapy 22 patients (79%) in whom nonsurgical modalities had failed were relieved completely of pain even during strenuous activity. [50] (10.1053/jhsu.2003.50041)
  • [L3] The efficacy of this autologous platelets is once again well established and this study reinforced categorically the previously published report by the author. [51] (10.1016/j.injury.2024.111469)
  • [L1] Spin bias is highly prevalent in the abstracts of systematic reviews and meta-analyses of intra-articular PRP to treat knee osteoarthritis, with identified spin tending to favor the use of PRP. [52] (10.1002/arj.70027)
  • [Paper] In this systematic review and meta-analysis, PRP demonstrated limited and inconsistent effects on imaging-based structural outcomes in knee OA, and did not confer significant and consistent benefits in medial tibial cartilage measurements, cartilage defect progression, synovitis, or most WORMS domains. [53] (10.1007/s00402-026-06543-6)
  • [L3] This systematic review indicates that PRP, used as an adjuvant in meniscal repair, may be associated with improved clinical and radiographic outcomes, particularly by reducing failure rates and enhancing PROs. [54] (10.1177/23259671261467213)
  • [L1] However, substantial heterogeneity and inconsistent reporting of PRP composition limit the certainty of this finding. [55] (10.1177/23259671261480483)

References

[1] Platelet-Rich Plasma for Chronic Tennis Elbow: Letters to the Editor. The American Journal of Sports Medicine. 2014. DOI: 10.1177/0363546513512784

[2] Update on Platelet-rich Plasma for Shoulder and Elbow Tendinopathy. Techniques in Shoulder & Elbow Surgery. 2017. DOI: 10.1097/bte.0000000000000118

[3] Efficacy of multiple autologous apheresis platelet-rich plasma injections for treating knee osteoarthritis and its influencing factors: a retrospective cohort study. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05756-6

[4] PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: Response. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465251387701

[5] Comparison of Conventional Dose Versus Superdose Platelet-Rich Plasma for Knee Osteoarthritis: Letter to the Editor. Orthopaedic Journal of Sports Medicine. 2024. DOI: 10.1177/23259671241255700

[6] Overview of Available Treatments and Their Limitations for Hypertrophic Facet Joints—A Systematic Review of the Literature. JAAOS: Global Research and Reviews. 2025. DOI: 10.5435/jaaosglobal-d-24-00140

[7] Letter Regarding “Platelet-Rich Plasma Injections are Inferior to Corticosteroid Injections for Short-Term Pain Relief: A Prospective, Double-Blinded, Randomized Controlled Trial”. The Journal of Arthroplasty. 2025. DOI: 10.1016/j.arth.2025.05.007

[8] Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis. Journal of Orthopaedic Surgery and Research. 2026. DOI: 10.1186/s13018-026-06689-4

[9] Union Rate and Time to Union Following Platelet-Rich Plasma Therapy in Fracture Nonunion: A Systematic Review and Meta-Analysis. Injury. 2026. DOI: 10.1016/j.injury.2026.113826

[10] PRP injection in musculoskeletal pathology: what level of evidence, and what recommendations?. Orthopaedics & Traumatology: Surgery & Research. 2026. DOI: 10.1016/j.otsr.2026.104972

[11] Degenerative osteoarthritis a reversible chronic disease. Regenerative Therapy. 2020. DOI: 10.1016/j.reth.2020.07.007

[12] The Effectiveness of Platelet-Rich Plasma Injections in Gluteal Tendinopathy: Response. The American Journal of Sports Medicine. 2018. DOI: 10.1177/0363546518773719

[13] Comparison of the effectiveness of platelet-rich plasma (PRP) injection and steroid injection in patients with bilateral moderate carpal tunnel syndrome: a prospective randomized controlled trial. Injury. 2026. DOI: 10.1016/j.injury.2026.113018

[14] Use of Platelet-Rich Plasma for the Improvement of Pain and Function in Rotator Cuff Tears: Response. The American Journal of Sports Medicine. 2020. DOI: 10.1177/0363546520918190

[15] Time-dependent growth factor kinetics, platelet concentration, and clinical response following platelet-rich plasma versus saline in chronic tenosynovitis: a randomized controlled trial. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-09339-8

[16] Platelet-rich plasma treatment for large joint osteoarthritis: retrospective study highlighting a possible treatment protocol with long-lasting stimulation of the joint with an adequate dose of platelets. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08663-3

[17] Platelet-Rich_Plasma_Versus_Hyaluronic_Acid_S0749806312015812. 2015.

[18] Improving Injectable Orthobiologics Reporting Guidelines Adherence: Response. The American Journal of Sports Medicine. 2023. DOI: 10.1177/03635465231203202

[19] Clinical Pathway Management for Platelet-Rich Plasma Therapy in Kellgren-Lawrence Grade I and II Knee Osteoarthritis: A Prospective, Multicenter, Double-Blind Randomized Controlled Trial. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465261486945

[20] A Randomized Controlled Trial of 1-Year Clinical Outcomes of a Single Platelet-Rich Plasma Injection Versus Corticosteroid for the Treatment of Lateral Elbow Tendinopathy. Orthopaedic Journal of Sports Medicine. 2026. DOI: 10.1177/23259671251386862

[21] Platelet-Rich Plasma in the Treatment of Musculoskeletal Disease in 2025 and Beyond. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465251395284

[22] Platelet Concentration Factor Explains Variability in Outcomes of Platelet-rich Plasma for Lateral Epicondylitis: High Dose Critical for Positive Response. Journal of ISAKOS. 2025. DOI: 10.1016/j.jisako.2025.100442

[23] The Anti-inflammatory and Matrix Restorative Mechanisms of Platelet-Rich Plasma in Osteoarthritis: Response to Patel and Dhillon. The American Journal of Sports Medicine. 2014. DOI: 10.1177/0363546514537991

[24] Hyaluronic Acid Versus Platelet-rich Plasma: Response. The American Journal of Sports Medicine. 2017. DOI: 10.1177/0363546517703364

[25] Platelet-Rich Plasma in Acute Muscle Injuries: An Umbrella Review and Meta-analysis of Return to Sport and Reinjury Outcomes. Orthopaedic Journal of Sports Medicine. 2026. DOI: 10.1177/23259671251399907

[26] Adherence rates to the Minimum Information for Studies Evaluating Biologics in Orthopedics guidelines for clinical studies on platelet-rich plasma for the treatment of lateral epicondylitis: a systematic review. Clinics in Shoulder and Elbow. 2026. DOI: 10.5397/cise.2024.01060

[27] Time to Resolution of Triggering after Steroid Injection for First Presentation Trigger Digits. The Journal of Hand Surgery (Asian-Pacific Volume). 2020. DOI: 10.1142/s2424835520500253

[28] Platelet-Rich Plasma Does Not Improve Pain or Function in Patients With Lateral Epicondylitis as Compared With Placebo: A Meta-analysis of Randomized Clinical Trials. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465251383039

[29] Orthobiologic Injections Adjunctive to Cartilage‐Preserving Surgery May Improve Outcomes for Focal Knee Chondral Defects: A Systematic Review of Randomized Controlled Trials With Subgroup Meta‐analyses. Arthroscopy. 2026. DOI: 10.1002/arj.70548

[30] PS9 Is platelet-rich plasma injection an effective choice in cases of delayed union or non-union?. Injury. 2013. DOI: 10.1016/s0020-1383(13)70158-x

[31] Muscle repair: platelet-rich plasma derivates as a bridge from spontaneity to intervention. Injury. 2014. DOI: 10.1016/s0020-1383(14)70004-x

[32] The Accurate Characterization of Platelet-Rich Plasma Enables Its Classification and Comparison: Response. The American Journal of Sports Medicine. 2023. DOI: 10.1177/03635465231206930

[33] Platelet‐Rich Plasma (PRP) From Older Males With Knee Osteoarthritis Depresses Chondrocyte Metabolism and Upregulates Inflammation. Journal of Orthopaedic Research. 2019. DOI: 10.1002/jor.24322

[34] Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. Journal of Orthopaedic Research. 2006. DOI: 10.1002/jor.20278

[35] Efficacy of platelet-rich plasma injections for chronic medial epicondylitis. Journal of Hand Surgery (European Volume). 2015. DOI: 10.1177/1753193414567012

[36] The efficacy of platelet-rich plasma preparation protocols in the treatment of osteoarthritis: a network meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06026-1

[37] Anti-inflammatory and Matrix Restorative Mechanisms of Platelet-Rich Plasma in Osteoarthritis: Response to Andia and Maffulli. The American Journal of Sports Medicine. 2014. DOI: 10.1177/0363546514537996

[38] Leukocyte-poor platelet-rich plasma reduces retear risk after arthroscopic rotator cuff repair: a meta-analysis with mechanistic and economic evaluation. Journal of Shoulder and Elbow Surgery. 2026. DOI: 10.1016/j.jse.2026.02.018

[39] Injection of Leukocyte‐Poor Platelet‐Rich Plasma During Rotator Cuff Repair Can Increase Healing Rate but Does Not Affect Clinical Outcomes: A Systematic Review and Meta‐analysis of Randomized Controlled Trials. Arthroscopy. 2026. DOI: 10.1002/arj.70537

[40] Comparative Efficacy of Leukocyte-Rich and Leukocyte-Poor PRP for Lateral Epicondylitis on Isokinetic and Isometric Upper Limb Strength under an Identical Rehabilitation Protocol: A Randomized Controlled Trial. Journal of Shoulder and Elbow Surgery. 2026. DOI: 10.1016/j.jse.2026.09.009

[41] Editor’s Spotlight/Take 5: Is Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials. Clinical Orthopaedics & Related Research. 2025. DOI: 10.1097/corr.0000000000003478

[42] PRP for Arthroscopic Repair of Medium to Large Rotator Cuff Tears: Response. The American Journal of Sports Medicine. 2016. DOI: 10.1177/0363546515625958

[43] Leukocytes Do Not Influence the Safety and Efficacy of Platelet-Rich Plasma Injections for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Controlled Trial. The American Journal of Sports Medicine. 2024. DOI: 10.1177/03635465241283500

[44] Efficacy of Platelet-Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome. Journal of Bone and Joint Surgery. 2025. DOI: 10.2106/jbjs.24.00763

[45] Efficacy of small-diameter core decompression with platelet-rich plasma in early osteonecrosis of the femoral head: a retrospective study. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-024-08243-x

[46] Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08566-3

[47] RETRACTED ARTICLE: A meta-analysis and systematic review of the clinical efficacy and safety of platelet-rich plasma combined with hyaluronic acid (PRP + HA) versus PRP monotherapy for knee osteoarthritis (KOA). Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-024-05429-w

[48] Poster 58: Decreased Pain After Platelet-Rich Plasma Injection in Lateral Epicondylitis Patients in the Early Follow-up Period. Orthopaedic Journal of Sports Medicine. 2025. DOI: 10.1177/2325967125s00169

[49] Investigating the therapeutic impact of platelet-rich plasma on knee, hip, and traumatic osteoarthritis: a meta-analysis and systematic review. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09486-6

[50] Autologous blood injections for refractory lateral epicondylitis. The Journal of Hand Surgery. 2003. DOI: 10.1053/jhsu.2003.50041

[51] Percutaneous injection of autologous platelet gel accelerate healing in diabetic tibial non union: On going longitudinal study. Injury. 2024. DOI: 10.1016/j.injury.2024.111469

[52] Statistically Significant Results Favored in Abstracts of Platelet Rich Plasma Treatment of Knee Osteoarthritis: A Systematic Review and Spin Analysis. Arthroscopy. 2026. DOI: 10.1002/arj.70027

[53] Platelet-rich plasma for knee osteoarthritis: a systematic review and meta-analysis of structural outcomes. Archives of Orthopaedic and Trauma Surgery. 2026. DOI: 10.1007/s00402-026-06543-6

[54] A Systematic Review of PRP Augmentation for Nondegenerative Meniscal Repair: Is There a Benefit?. Orthopaedic Journal of Sports Medicine. 2026. DOI: 10.1177/23259671261467213

[55] Platelet Concentration Is Not Associated With Improved Pain for Partial-Thickness Rotator Cuff Tears Treated With Platelet-Rich Plasma: A Systematic Review and Meta-analysis With Meta-regression of Level 1 Randomized Controlled Trials. Orthopaedic Journal of Sports Medicine. 2026. DOI: 10.1177/23259671261480483

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International


Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees


Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.


Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.